美国 · 财经报刊 · Investor's Business Daily

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

来源：Investor's Business Daily · 美国 4 小时前

Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole. The post Why Biohaven Catapulted 30%-Plus —…

在 Investor's Business Daily 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.investors.com)

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

推荐阅读

U.S. 10-Year Treasury Yield Falls Under 5% as French Turmoil Fuels Flight for Safety

Alibaba Stock Slips as China Renews Regulatory Pressure

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

分享

推荐阅读

U.S. 10-Year Treasury Yield Falls Under 5% as French Turmoil Fuels Flight for Safety

Alibaba Stock Slips as China Renews Regulatory Pressure